Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,024 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.
Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Gomi S, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Nakajima N, Marumo A, Omori I, Fujiwara Y, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K. Sakaguchi M, et al. Among authors: uchiyama h. Blood Adv. 2018 Oct 23;2(20):2744-2754. doi: 10.1182/bloodadvances.2018020305. Blood Adv. 2018. PMID: 30341082 Free PMC article.
Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution.
Matsumoto Y, Taki T, Fujimoto Y, Taniguchi K, Shimizu D, Shimura K, Uchiyama H, Kuroda J, Nomura K, Inaba T, Shimazaki C, Horiike S, Taniwaki M. Matsumoto Y, et al. Among authors: uchiyama h. Int J Hematol. 2009 Apr;89(3):352-358. doi: 10.1007/s12185-009-0268-7. Epub 2009 Mar 24. Int J Hematol. 2009. PMID: 19308660
beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S, Maekawa T. Ashihara E, et al. Among authors: uchiyama h. Clin Cancer Res. 2009 Apr 15;15(8):2731-8. doi: 10.1158/1078-0432.CCR-08-1350. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351774
Early ultrasonographic diagnosis and clinical follow-up of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in a patient with acute lymphoblastic leukemia.
Matsumoto Y, Horiike S, Sakagami J, Fujimoto Y, Taniguchi K, Shimizu D, Shimura K, Uchiyama H, Kuroda J, Nomura K, Shimazaki C, Taniwaki M. Matsumoto Y, et al. Among authors: uchiyama h. Intern Med. 2009;48(10):831-5. doi: 10.2169/internalmedicine.48.1404. Epub 2009 May 15. Intern Med. 2009. PMID: 19443980 Free article.
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, Tanaka T, Kamitsuji Y, Murakami S, Hatsuse M, Okano A, Iwai T, Ueda S, Koshida M, Uchiyama H, Matsumoto Y, Kaneko H, Uoshima N, Ueda Y, Kobayashi Y, Shimazaki C, Horiike S, Taniwaki M. Kobayashi T, et al. Among authors: uchiyama h. Int J Hematol. 2010 Nov;92(4):579-86. doi: 10.1007/s12185-010-0696-4. Epub 2010 Oct 7. Int J Hematol. 2010. PMID: 20924731
ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin.
Ohshiro M, Kuroda J, Kobayashi Y, Akaogi T, Kawata E, Uoshima N, Kamitsuji Y, Kaneko H, Shimura K, Shimazaki C, Murakami S, Hatsuse M, Okano A, Kobayashi T, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Ohshiro M, et al. Among authors: uchiyama h. Am J Hematol. 2012 Jan;87(1):116-9. doi: 10.1002/ajh.22185. Epub 2011 Oct 12. Am J Hematol. 2012. PMID: 21989545 Free article. Clinical Trial. No abstract available.
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Among authors: uchiyama h. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Murakami S, Hatsuse M, Okano A, Iwai T, Tsutsumi Y, Kamitsuji Y, Akaogi T, Kawata-Iida E, Shimizu D, Uchiyama H, Matsumoto Y, Horiike S, Nakao M, Takahashi R, Kaneko H, Uoshima N, Kobayashi Y, Shimazaki C, Taniwaki M. Kobayashi T, et al. Among authors: uchiyama h. Intern Med. 2013;52(9):961-8. doi: 10.2169/internalmedicine.52.9385. Epub 2012 Mar 1. Intern Med. 2013. PMID: 23648714 Free article.
1,024 results